February 2012
- Immunotherapy: a new hope for GIST treatment
- Gleevec: revolutionizing GIST cancer treatment
- Illustrating gives Greenwood comfort through his GIST battle
- Gratz, 64, fought a courageous battle
- The use of mouse models to help investigate GIST
- March 2007 clinical trial update
March 2007
- Immunotherapy: a new hope for GIST treatment by Estelle LeCointe A French phase I clinical trial, combining Gleevec + interleukin 2 (IL-2) should open in April 2007 at the Institute Gustave Roussy in Villejuif, France.
- Gleevec: revolutionizing GIST cancer treatment by Jerry Call In this month’s March 2007 newsletter, Estelle LeCointe, the director of Association Française des Patients du GIST: Ensemble contre le GIST, has shared the story of the work of Professor Laurence Zitvogel. Professor Zitvogel and her colleagues are engaged in a project combining Gleevec and immunotherapy. It has been very interesting to watch this work evolve over the last few years. This research has culminated in the discovery of a new type of immune cell (in mice) and is poised to enter clinical trials in 2007.
- Illustrating gives Greenwood comfort through his GIST battle by Erin Kristoff For Peter Greenwood, a successful freelance illustrator, GIST is a burden and a tool. Like most GIST patients he feels the pressure of scans and occasional hopelessness. But despite all of this, Peter has found ways to use GIST to his advantage, to use it for inspiration by using his illustrations as tools to fight GIST.
- Gratz, 64, fought a courageous battle Stephen K. “Steve” Gratz, age 64, of Savage, Minn., passed away peacefully at his home surrounded by his family after losing a courageous battle with GIST cancer on Feb. 1, 2007.
- The use of mouse models to help investigate GIST by Peter Besmer, M.D. In this newsletter I would like to highlight the importance and usefulness of mice or mouse models in biological and cancer research by using the Kit receptor tyrosine kinase as an example.
- March 2007 clinical trial update by Jim Hughes